Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents?

por Nurmohamed, Nick S, Ditmarsch, Marc, Kastelein, John J P
Publicado 2021

CETP and SGLT2 inhibitor combination therapy improves glycemic control

por Khomtchouk, Bohdan B., Sun, Patrick, Ditmarsch, Marc, Kastelein, John J.P., Davidson, Michael H.
Publicado 2023

Comparison of low-density lipoprotein cholesterol equations in patients with dyslipidaemia receiving cholesterol ester transfer protein inhibition

por Martin, Seth S, Ditmarsch, Marc, Simmons, Mark, Alp, Nicholas, Turner, Traci, Davidson, Michael H, Kastelein, John J P
Publicado 2022

Cholesteryl Ester Transfer Protein Inhibition Reduces Major Adverse Cardiovascular Events by Lowering Apolipoprotein B Levels

por Nelson, Adam J., Sniderman, Allan D., Ditmarsch, Marc, Dicklin, Mary R., Nicholls, Stephen J., Davidson, Michael H., Kastelein, John J. P.
Publicado 2022